Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 2 trial of CagriSema in type 2 diabetes mellitus (T2DM), diabetic peripheral neuropathy (DPN), sponsored by Novo Nordisk. Started Jan 2025; status: completed.
02
Drugs
CagriSema
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT06797869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797869.